CSBio CSBio

X
[{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of KAN-101 in Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Anokion SA"},{"orgOrder":0,"company":"Calypso Biotech SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calypso Biotech Doses First Patient First Phase 1 Cohort with Anti-IL-15 Monoclonal Antibody CALY-002 to Treat Autoimmune Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Calypso Biotech SA"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Kanyos Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces Positive Data from Phase 1 ACED Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease Presented in a Plenary Session at DDW 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Anokion SA"},{"orgOrder":0,"company":"Calypso Biotech SA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"$250.0 million","newsHeadline":"Calypso Enters into Agreement to be Acquired by Novartis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Calypso Biotech SA"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastro-intestinal and rheumatology indications. CALY-002 is a potential best-in-class therapeutic antibody that binds to and neutralizes Interleukin-15.

            Lead Product(s): CALY-002

            Therapeutic Area: Gastroenterology Product Name: CALY-002

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: $425.0 million Upfront Cash: $250.0 million

            Deal Type: Acquisition January 08, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            KAN-101 is an investigational drug that aims to re-educate the immune cells that drive celiac disease, so they do not respond to gluten antigens, while leaving the healthy components of the immune system intact.

            Lead Product(s): KAN-101

            Therapeutic Area: Gastroenterology Product Name: KAN-101

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Kanyos Bio

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Calypso Biotech has elected Celiac Disease and Eosinophilic Esophagitis to evaluate the biological and clinical efficacy of CALY-002. The study is a multi-site, randomized, placebo controlled single and multiple dose escalation study of an anti-IL-15 mAb (CALY-002).

            Lead Product(s): CALY-002

            Therapeutic Area: Gastroenterology Product Name: CALY-002

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 16, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            First-in-human study designed to evaluate the safety and tolerability of KAN-101 in patients with celiac disease on a gluten-free diet (GFD).

            Lead Product(s): KAN-101

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY